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Key points  
Question: Does cooling of the brain, initiated prehospital during cardiopulmonary 
resuscitation, improve neurologic intact survival in patients with out-of-hospital cardiac arrest? 
 
Findings: In this randomized clinical trial of 677 patients with out-of-hospital cardiac arrest, 
good neurologic outcome (Cerebral Performance Category 1–2) was 16.6% in the trans-nasal 
cooling group compared with 13.5% in the usual care group, a difference that did not reach 
statistical significance.  
 
Meaning: Trans-nasal evaporative intra-arrest cooling did not result in a statistically significant 
improvement in neurologic intact survival. 
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Abstract  
Importance: Therapeutic hypothermia may increase neurologic intact survival after cardiac 
arrest. Trans-nasal evaporative cooling is a method to induce cooling during cardiopulmonary 
resuscitation (i.e. intra-arrest), primarily of the brain. 	
Objective: To determine whether pre-hospital trans-nasal evaporative intra-arrest cooling 
improves neurologic intact survival compared with cooling initiated after hospital arrival.  
Design, Setting, Participants: The PRINCESS trial was an investigator-initiated, 
randomized clinical, international multicenter study with blinded assessment of the outcome, 
performed by emergency medical services in seven European countries from July 2010 to 
January 2018, with final follow up April 30, 2018. In total, 677 patients with bystander-
witnessed out-of-hospital cardiac-arrest were enrolled.  
Interventions: Patients were randomly assigned to trans-nasal evaporative intra-arrest cooling 
(n=343) or standard care (n=334). Patients admitted to hospital in both groups received 
systemic therapeutic hypothermia, at 32–34 ºC, for 24 hours. 
Main outcomes and Measures: Primary outcome was neurologic intact survival, Cerebral 
Performance Category (CPC) 1–2, at 90 days. Among secondary outcomes were: survival at 90 
days; and time to reach core body temperature of <34 ºC.   
Results: Among the 677 randomized patients (median age 65; 172 [25%] women) 671 
completed the trial. Median time to core temperature <34 ºC was 105 min in the intervention 
group versus 182 min in controls, p< .001. The proportion of patients with CPC 1–2, at 90 days 
was 16.6% (56/337) in the intervention group versus 13.5% (45/334) in controls (difference 
3.1%; 95% confidence interval [CI], -2.3% to 8.5%; relative risk [RR] 1.23 [0.86–1.72], p= 
.25). Survival at 90 days was 17.8% (60/337) versus 15.6% (52/334) respectively (difference 
2.2%; 95% CI, -3.4% to 7.9%; RR 1.14 [0.81–1.57, p= .44). Minor nosebleed was the most 
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common device-related adverse event, reported in 13% of the patients in the intervention group 
(45/337). The adverse event rate within 7 days was similar between groups.  
Conclusions and Relevance: Among patients with out-of-hospital cardiac arrest, trans-nasal 
evaporative intra-arrest cooling compared with usual care did not result in a statistically 
significant improvement in neurologic intact survival at 90 days.  
 
Trial Registration: ClinicalTrials.gov Identifier: NCT01400373 
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INTRODUCTION  
 
Therapeutic hypothermia may increase survival with good neurologic outcome after out-of-
hospital cardiac arrest.1 Experimental data show that therapeutic hypothermia in cardiac arrest 
reduces ischemic and reperfusion brain injury, with a beneficial effect of early, intra-arrest 
cooling, i.e. started during cardiopulmonary resuscitation (CPR), compared with cooling 
initiated at a later stage.2-4 Despite this, the majority of clinical studies have concerned the 
effect of therapeutic hypothermia when cooling was initiated after hospital arrival, most often 
at the intensive care unit (ICU), several hours after the cardiac arrest.1,5 Currently, treatment 
guidelines recommend hospital use of therapeutic hypothermia or temperature control at a 
temperature of 32 °C to 36 °C for at least 24 hours, with the strongest indication in patients 
with ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) as first rhythm.6,7   
Clinical trials assessing the effect of early, pre-hospital cooling have in general involved the 
use of infusions of cold fluids administered intra-arrest or early after return of spontaneous 
circulation (ROSC).8-11 Cold fluids cool the patient effectively, but seem to have significant 
hemodynamic side effects.11 In particular, this has been observed in patients with VF as first 
rhythm, where intra-arrest infusion of cold fluid decreased the rate of patients achieving 
ROSC.9 Based on these findings, pre-hospital cooling using rapid infusion of cold intravenous 
fluid is not recommended.6,7 
Trans-nasal evaporative cooling is a method that does not add volume to the patient. This 
non-invasive cooling method can be induced intra-arrest and leads to continuous cooling, 
primarily of the brain.12,13 The primary objective of this study was to determine whether pre-
hospital trans-nasal evaporative intra-arrest cooling improves survival with good neurologic 
outcome, compared with current practice where cooling is initiated after hospital arrival. 
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METHODS 
 
Trial design 
The PRINCESS trial was an investigator-initiated, randomized clinical trial with blinded 
assessment of the outcome. The study was conducted in 11 Emergency Medical Services 
(EMSs) in seven European countries between 07-01-2010 and 01-31-2018. The last patient 
was followed-up on April 29, 2018. Ethics and institutional committees in each participating 
country approved the study protocol and statistical analysis plan (Supplement 1) and the 
rationale and design of the trial have been published previously.14 An independent Data and 
Safety Monitoring (DSM) committee reviewed predefined endpoints at interim analyses after 
recruitment of 200 and 500 randomized patients. After the interim analysis at 500 patients, 
further recruitment of study patients by helicopter EMSs was stopped because of prolonged 
times to inclusion, being regarded as a safety issue. The study was conducted according to the 
requirements of the Declaration of Helsinki. Written informed consent was obtained from the 
closest relative or a legal representative after hospital admission, and, at a later stage, from 
each patient who regained mental capacity. Neither EMS nor hospital personnel were blinded 
to treatment, because of the nature of the intervention. However, nurses/physicians 
performing neurological assessment of patients prior to discharge and at 90 days, as well as 
data managers and researchers were blinded to the patients’ group assignment.  
 
Patients 
The inclusion criteria were bystander-witnessed cardiac arrests in patients of ≥18 years of age. 
Exclusion criteria were patients aged ≥80 years; an etiology of cardiac arrest due to trauma, 
head trauma, severe bleeding, drug overdose, cerebrovascular accident, drowning, smoke 
inhalation, electrocution, hanging; already hypothermic; an obvious anatomic barrier to 
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placing intra-nasal catheters; an existing do not attempt resuscitation (DNAR) order; known 
terminal disease; known or clinically apparent pregnancy; known coagulopathy (except 
therapeutically induced); need for supplemental oxygen; patients that achieved ROSC prior to 
randomization; EMS response time (collapse to EMS arrival) >15 minutes.  
 
Randomization and trial intervention 
Patients were screened for eligibility by the advanced life-support team after airway 
management (i.e. endotracheal intubation or laryngeal mask). If the study criteria were 
fulfilled, patients were randomly assigned (1:1 ratio) to either intra-arrest cooling or standard 
care, using sequentially numbered envelopes, which were provided by the Karolinska Institute 
to the participating study site. Randomization was generated in blocks of four without 
stratification. Both study groups received standard advanced life-support care according to 
international guidelines. In patients randomized to intervention, trans-nasal evaporative 
cooling was initiated intra-arrest. The cooling method delivers a mixture of air or oxygen and 
a liquid coolant (perfluorohexane) via nasal catheters. When the coolant evaporates, it absorbs 
heat from the surrounding tissue and rapidly cools the nasal cavity to about 2 °C. The method 
was developed primarily to cool the brain, as it takes advantage of the nasal pathways (i.e., 
the conchal folds and turbinates) that provide a highly vascular and large, diffuse surface area 
that is in close proximity to the cerebral circulation. The method has previously been 
described in detail.12,14,15 If the patient achieved ROSC or was transported during CPR to 
hospital, trans-nasal evaporative cooling was continued until hospital arrival and whenever 
possible until systemic hospital cooling was initiated.  
Hospital-admitted patients received post-resuscitation treatment according to current 
treatment guidelines, including systemic hypothermia for both study groups.16  
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Intravenous sedation, analgesia and neuromuscular blockade were used according to 
institutional cooling protocols. The targets for ventilation settings, mean arterial blood 
pressure and glucose control have been described previously.14 The temperature was 
measured according to local practices in the urinary bladder, rectum, esophagus, or with 
intravascular probes. The target core temperature for all patients was 33 °C ± 1 °C and the 
duration of hypothermia was 24 hours. The re-warming rate was 0.2–0.5 °C per hour. 
Temperature control to avoid fever was recommended for 72 hours. 
 
Data collection 
Data on factors at resuscitation, e.g. age, bystander CPR and initial rhythm followed the 
template recommended by guidelines.17 The advanced life-support team recorded pre-hospital 
event times and temperature measurements at ROSC. Tympanic and core temperature was 
measured after hospital arrival and during the first 72 hours. In-hospital measures were 
recorded, such as coronary angiography, intra-aortic balloon pump use and neurologic 
prognostic measures. Data on adverse events were collected up to and including day seven 
following admission. At 90 days, data on good functional recovery was collected by means of 
a structured interview over the phone or person-to-person, using the Pittsburgh cerebral 
performance category (CPC) scale,18 where CPC 1 is good recovery (alert and has normal 
cerebral function), CPC 2 represents moderate disability (alert and has sufficient cerebral 
function to live independently and work in a sheltered environment), CPC 3, severe disability 
(conscious but dependent on others for daily support), CPC 4, vegetative state (any degree of 
coma without the presence of all brain-death criteria), and 5, dead. In addition, good 
functional recovery assessment according to the Modified Rankin scale was performed at 90 
days (Supplement 2). 
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Outcomes 
The primary outcome was survival with good neurologic outcome 90 days after arrest, 
defined as a CPC score of 1 or 2.  
The secondary outcomes were (1) overall survival rate at 90 days, and (2) cooling efficacy 
measured as time from collapse to core temperature of <34 °C.14  
Two secondary endpoints, “sustained ROSC” (defined in the protocol as ROSC >20 minutes) 
and “admitted alive to hospital” were post-hoc merged into one variable “sustained ROSC 
and admitted alive” as the EMS crew did not correctly report sustained ROSC according to 
the protocol definition. To be “admitted alive” also requires sustained ROSC.  
Adverse events were reported as device-related adverse events within 24 hours and adverse 
events at hospital within the first seven days after randomization. 
Post-hoc endpoints were proportion of patients achieving sustained ROSC and admitted alive 
to hospital; survival with CPC 1 at 90 days; and the full distribution of CPC scores and 
Modified Rankin Scale scores at 90 days.  
 
Statistical analyses 
Power calculation was based on the preceding safety and feasibility trial that showed an 
absolute difference of 16% (21% versus 37%) in survival with CPC 1-2 at discharge among 
the patients admitted alive at hospital.12 To show this absolute difference of 16% in the 
primary outcome patients a sample size of 150 patients admitted alive to hospital in each 
study arm was required for 80% power (2-sided, alpha level of 0.05). This would require a 
total sample of 650 to 800 patients to be randomized pre-hospital depending on the proportion 
of those patients that was resuscitated and admitted to hospital.14 After recommendations 
from the DSM committee, the primary outcome analyses were performed in all randomized 
patients instead of those who were admitted alive to hospital.  
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The primary analyses were performed on all randomized patients, except those allocated to 
intervention that did not fulfill study criteria and never received the intervention (n=6). 
Continuous variables that were not normally distributed are reported as medians and 
interquartile ranges. Categorical variables are reported as counts and percentages. Primary 
analysis for the efficacy endpoints was conducted with Pearson’s χ2 tests for comparison of 
binominal proportions. As a post-hoc analyze, generalized linear mixed-effect models with 
study site as a random variable was used to calculate relative differences between categorical 
variables. Odds ratios were converted to relative risks (RRs) with 95% confidence intervals 
(CIs).19  For continuous endpoints (time to core temperature <34 °C) the Hodges–Lehmann 
estimator was used. 
The secondary analysis was performed as a “per-protocol” analysis that was restricted to all 
randomized patients with adherence to the intervention (i.e. excluded those in the intervention 
group that did not receive intra-arrest cooling). The secondary analysis was performed in 
accordance with the primary analysis.  
Analyzes on the primary, secondary and exploratory endpoints were performed in pre-
specified subgroups: patients with VF/VT as the initial rhythm; and patients where EMSs 
started CPR in less than 10 minutes. Exploratory endpoints (post-hoc), i.e. CPC 1 and the 
distribution of neurologic scores, were analyzed as absolute differences in proportions with 
95% CI.  
Multiple imputations have not been performed, as we had no missing values for primary and 
main secondary outcome (i.e. overall survival at 90 days). 
All probability values were 2-sided, with values less than .05 regarded as statistically 
significant. No post-hoc adjustment of the significance level was performed. Because of the 
potential for type 1 error due to multiple comparisons, findings for analyses of secondary 
endpoints should be interpreted as exploratory. Post-hoc analyses on CPC1 and the 
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distribution of neurologic scores should also be considered as exploratory. Statistical analyses 
were performed with R (version 3.4.3) 
 
 
RESULTS  
Patients 
Among 677 randomized patients,  671 (337 intervention and 334 control) were included in the 
primary analysis, see Figure 1.  
 
Baseline characteristics  
Patient characteristics, factors at the scene of the arrest, resuscitation measures, and event 
times prior to randomization were similar in the two groups (Table 1).  
 
Event times, prehospital and hospital factors  
In patients randomly assigned to intra-arrest cooling, the median time to start of cooling was 
19 minutes from collapse. Tympanic temperatures at ROSC were 35.7 versus 36.0 ºC 
(p=0.02). At hospital arrival at a median time of 25 minutes post-ROSC, temperatures were 
34.6 versus 35.8 ºC, p<0.001(eFigure 5, Supplement 2). Characteristics and measures after 
hospital arrival were similar in the two groups (Table 2).  
 
Outcome  
Primary outcome  
In the primary analysis, the proportion of patients who survived with good neurologic 
function (CPC 1–2) at 90 days was 16.6% (56/337) in the intervention group versus 13.5% 
(45/334) in controls (difference 3.1%; 95% CI -2.3% to 8.5%; RR 1.23 [0.86–1.72], p= .25; 
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Table 3, eFigure 2, Supplement 2).  In the secondary, per-protocol, analysis, the rate of CPC 
1–2 at 90 days was 17.1% (56/328) versus 13.5% (45/334) respectively (difference 3.6%; 
95% CI -1.9% to 9.1%; RR 1.26 [0.88–1.75], p= .20; eTable 1, Supplement 2). Primary 
outcome analysis for those patients admitted alive to hospital is presented in eTable 2, 
Supplement 2.   
 
Secondary outcomes  
Overall survival at 90 days was 17.8% (60/337) in the intervention group versus 15.6% 
(52/334) in controls (difference 2.2%; 95% CI -3.4% to 7.9%; RR 1.14 [0.81–1.57], p= .44; 
Table 3). Times to target core temperature were 105 min. in the intervention group versus 182 
min. in controls (p< .001). Secondary outcomes in the secondary, per protocol, analysis are 
presented in the eTable1, Supplement 2.  
 
Pre-defined subgroup analyses  
In patients with VF or pulseless ventricular tachycardia (VT) as first rhythm the proportions 
of those with CPC 1–2 at 90 days were 34.8% (48/138) in the intervention group and 25.9% 
(35/135) in controls (difference 8.9%; 95% CI -2.0 to 19.7%; RR 1.28 [0.90–1.72], p= .11; 
Table 3; eFigure 3, Supplement 2). The p-value for interaction was  .31. For further subgroup 
analyses, see Figure 2.  
 
Post-hoc analyses  
The proportion that achieved sustained ROSC and were admitted alive to hospital was 44.2% 
(149/337) in the intervention group versus 42.5% (142/334) in controls (difference 1.7%; 
95% CI -5.8% to 9.2%; RR 1.04 [0.87–1.22], p= .66).   
The proportion of CPC 1 was 14.8% (50/337) in the intervention group versus 10.5% 
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(35/334) in controls (difference 4.4%; 95% CI -0.7% to 9.4%; RR 1.40 [0.95-2.01]), see 
Figure 3. In the subgroup with VF or pulseless VT the proportion of patients with CPC 1 was 
32.6% (45/138) versus 20% (27/135) (difference 12.6%; 95% CI 2.3 to 22.9%; RR 1.54 
[1.06-2.06]).  The distribution of CPC categories is shown in Figure 3.  Modified Rankin 
scale scores at 90 days are presented in eTables 6, Supplement 2.  
 
Adverse events 
Nosebleeds and nasal whitening were the most common device-related adverse events. In four 
patients cooling had to be stopped because of relatively severe nose bleeding. In one patient a 
CT scan showed pneumocephalus, which was seen as a serious device-related complication 
with probable intra-cerebral air leakage from the sinuses. The pneumocephalus was found to 
be resolved in the second CT scan after 10 days. The patient recovered and was assessed as 
CPC 2 at 90 days. Overall adverse events within seven days as regards bleeding that requires 
transfusion, pneumonia, recurrence of VF or VT, cardiogenic shock, pulmonary edema and 
seizures were 170/337 (50%) versus 163/334 (49 %). Detailed data on adverse events are 
presented in eTable 5, Supplement 2.   
 
 
 
DISCUSSION 
The main finding of this randomized clinical trial, including 677 patients with out-of-hospital 
cardiac arrest, was that trans-nasal intra-arrest cooling at the scene of collapse compared with 
standard systemic cooling at the ICU did not result in a statistically significant improvement 
in neurologic intact survival at 90 days.   
 
The group that received intra-arrest cooling had significantly shorter time intervals required to 
reach target core-body temperature. The overall adverse event rate reported within seven days 
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of randomization was similar in the two treatment groups. These results were consistent 
across predefined subgroups.  
  
In the light of previous studies, the safety aspects of a prehospital cooling method are 
important. Cold intravenous fluid decreases coronary perfusion pressure by augmenting the 
central venous pressure.20 This may partly explain the lower rate of ROSC observed in a 
randomized clinical trial when cold fluid was used intra-arrest in patients with ventricular 
fibrillation9 and the increased number of patients with re-arrest and pulmonary edema when 
cold fluids have been administered post-ROSC.11   Trans-nasal evaporative cooling does not 
add volume to the patient and could in this trial be initiated intra-arrest without the 
hemodynamic adverse events seen with cold intravenous fluids.9,11 Thus, intra-arrest cooling 
does not appear to have major harm when used in a prehospital setting among patients with 
cardiac arrest.  
 
The differences in neurologic intact survival at 90 days were not statistically significant. 
There may be several reasons for this. The cooling intervention might not be effective enough 
to lower temperature during CPR to mitigate brain injuries secondary to the ischemia and 
reperfusion process. The start of cooling might have been too late to provide the benefit seen 
in experimental models where such cooling is immediately applied.3,21 In this study, the 
cooling devices were placed in the second emergency vehicle with advanced life support 
capacity, which influenced the delay between start of CPR by EMS in the first vehicle and 
start of cooling. When comparing the results with those of the previous safety and feasibility 
study12, the control group performed significantly better in terms of cooling interval (i.e. 
smaller difference between groups in time required to reach target core temperature), overall 
survival and good neurologic outcome. As power estimations were based on these findings, 
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this study may have been underpowered to be able to detect important clinical differences.  
  
Patients with out-of-hospital cardiac arrest with initial rhythm of VF have the strongest 
recommendation for temperature management in current guidelines.6,7  The explorative 
findings in this subgroup of patients may be of importance to define the study population for 
future hypothermia trials.  Survival with complete neurologic recovery without any sequelae, 
e.g. only CPC 1, is the best outcome after cardiac arrest. As a post-hoc exploratory finding, 
there was a higher proportion of patients with CPC 1 in the intra-arrest cooling group 
compared with standard care.   
 
Limitations 
This study has several limitations. First, pre-hospital and hospital personnel were not blinded 
to treatment. Second, the study period was long and many eligible patients with cardiac arrest 
were not included in the trial, which may have introduced a risk of bias. Third, the study may 
have been underpowered to detect a clinically important difference in the primary outcome. A 
larger trial might have allowed detection or rejection of such a difference. 
 
Conclusions 
Among patients with out-of-hospital cardiac arrest, trans-nasal evaporative intra-arrest 
cooling compared with usual care did not result in a statistically significant improvement in 
neurologic intact survival at 90 days.  
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Figure legends.  
 
Figure 1. Randomization, follow up and analysis of patients in the PRINCESS trial.  
 
Figure 2. Probability of survival with neurologic intact survival, cerebral performance 
category (CPC) 1-2, 90 days after cardiac arrest (primary outcome).   
 
Figure 3. Distribution of cerebral performance category (CPC) scale scores in all patients and 
in the subgroup of patients with shockable rhythm.  
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Table	1.	Baseline	characteristics	prior	to	randomization.																																													 Intervention										 Control																																																									 n=337																			 n=334																			
Demographic	characteristics	 	 	Age	in	years,	median	[IQR]	(n)											 64	[55-72]	(328)					 66	[56-72]	(329)					Height	in	cm,	median	[IQR]	(n)											 177	[170-180]	(306)		 177	[170-180]	(307)		Weight	in	kg,	median	[IQR]	(n)											 85	[74-95]	(307)					 85	[75-95]	(304)					Male,	no./n	(%)																													 253/336	(75.3)								 252/333	(75.7)								Female,	no./n	(%)																											 83/336	(24.7)									 81/333	(24.3)										 	 	
Resuscitation	characteristics	 	 	Location	outside	home,	no./n	(%)												 123/300	(41.0)								 108/306	(35.3)								Presumed	cardiac	cause,	no./n	(%)											 260/308	(84.4)								 267/311	(85.9)								Shockable	rhythm,	no./n	(%)																	 138/336	(41.1)								 135/334	(40.4)								Bystander	CPR,	no./n	(%)																				 208/321	(64.8)								 194/325	(59.7)								CPR	by	first	responder,	no./n	(%)											 186/306	(60.8)								 205/312	(65.7)																																																				 																						 																						
Airway																																						 																						 																						Intubation,	no./n	(%)																							 259/328	(79.0)								 248/322	(77.0)								Laryngeal	mask,	no./n	(%)																			 63/328	(19.2)									 71/322	(22.0)									Laryngeal	tube,	no./n	(%)																			 6/328	(1.8)											 3/322	(0.9)																																																							 																						 																						
Medical	history																												 																						 																						Uncertain,	no./n	(%)																								 75/259	(29.0)									 72/262	(27.5)									Coronary	artery	disease,	no./n	(%)										 55/259	(21.2)									 65/262	(24.8)									None	known,	no./n	(%)																							 56/259	(21.6)									 53/262	(20.2)									Hypertension,	no./n	(%)																					 49/259	(18.9)									 49/262	(18.7)									COPD,	no./n	(%)																													 13/259	(5.0)										 8/262	(3.1)											Cardiac	failure,	no./n	(%)																		 9/259	(3.5)											 11/262	(4.2)										Pulmonary	embolism,	no./n	(%)															 2/259	(0.8)											 4/262	(1.5)																																																							 																						 																						
Key	times																																			 																						 																						Time	to	CPR	by	EMS,	median	[IQR]	(n)					 9	[6-12]	(292)							 9	[7-13]	(297)							Time	to	ALS	arrival,	median	[IQR]	(n)				 13	[9-18]	(287)						 13	[9-18]	(300)						Time	to	airway,	median	[IQR]	(n)									 14	[11-18]	(251)					 14	[11-17]	(272)					Time	to	randomization,	median	[IQR]	(n)		 17	[13-22]	(294)					 16	[12-21]	(299)								
Abbreviations: Shockable rhythm = ventricular fibrillation or pulseless ventricular tachycardia. CPR = cardiopulmonary 
resuscitation. EMS = emergency medical services. ALS = advanced life support. IQR=inter quartile range.  
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Table	2.	Post-randomization	characteristics	and	measures.																																																																 Intervention		n=337														 Control	n=334																			
Prehospital	characteristics																																													 																							 																							Adrenaline,	mg,	median	[IQR]	(n)																							 6	[4-8]	(290)													 5	[3-8]	(284)												Amiodarone,	mg,	median	[IQR]	(n)																								 300	[300-450]	(112)							 300	[300-450]	(80)							Duration	CPR	by	EMS,	minutes,	median	[IQR]	(n)														 30	[15-40]	(289)										 23	[10-36]	(300)									Achieved	any	ROSC,	no./n	(%)																																																																																																																								183/333 (55.0) 152/332	(45.8)												Ongoing	CPR	to	hospital,	no./n	(%)																		 41/333	(12.3)														 55/332	(16.6)													New	prehospital	cardiac	arrest,	no./n	(%)																																																																34/202 (16.8)														 25/185	(13.5)													Time	to	prehospital	cooling,	minutes,	median	[IQR]	(n)						 19	[15-25]	(317)										 	NA										Time	to	ROSC,	minutes,	median	[IQR]	(n)																					 30	[22-40]	(178)										 27	[21-38]	(151)									Tympanic.	temperature	at	ROSC,	ºC,	median	[IQR]	(n)									 35.8	[35.0,	36.4]	(132)				 36.0	[35.5,	36.5]	(92)				Time	to	Hospital	arrival,	minutes	median	[IQR]	(n)											 51	[43-63]	(126)										 54	[40-64]	(120)									
Characteristics	at	hospital	admission	a														 n=149																								 n=142																							Tympanic.	temperature	at	ED,	ºC,	median	[IQR]	(n)											 34.8	[34.2,	35.7]	(90)					 35.7	[35.4,	36.0]	(73)				Glasgow	Coma	Scale,	median	[IQR]	(n)																					 3	[3-3]	(110)													 3	[3-4]	(95)													PaO2,	mmHg,	median	[IQR]	(n)																										 98	[68-225]	(92)											 98	[68-218]	(82)										PaCO2,	mmHg,	median	[IQR]	(n)																									 45	[53-83]	(106)											 45	[53-83]	(97)											pH	value,	median	[IQR	(n)																															 7.1	[6.9,	7.2]	(111)							 7.1	[7.0,	7.2]	(99)							Base	excess,	mmol/l,	median	[IQR]	(n)																			 -14.0	[-19.7,	-8.9]	(103)		 -12.2	[-15.6,	-9.7]	(94)		Lactate,	mmol/l,	median	[IQR]	(n)																							 10.2	[7.7,	14.4]	(99)						 10.3	[7.4,	13.9]	(93)					Heart	rate,	min-1	,	median	[IQR]	(n)																	 82	[72-98]	(113)										 87	[74-100]	(99)									Systolic	blood	pressure,	mmHg,	median	[IQR]	(n)									 117	[99-135]	(89)									 115	[102-130]	(79)							Mean	arterial	pressure,	mmHg,	median	[IQR]	(n)										 74	[63-93]	(106)										 80	[68-87]	(90)										SpO2,	%,	median	[IQR]	(n)																															 97	[94-99]	(107)										 97	[93-99]	(98)										EtCO2,	median	[IQR]	(n)																																		 43	[35-52]	(29)											 43	[38-55]	(22)										Spontaneous	breathing,	no./n	(%)																		 20/106	(18.9)														 28/85	(32.9)														ST-elevation/new	LBBB	on	ECG,	no./n	(%)																		 39/114	(34.2)														 32/99	(32.3)														ST-depression	>1mm	on	ECG,	no./n	(%)																		 26/106	(24.5)														 35/93	(37.6)														
Revascularization	and	circulatory	support	a	 	 	Angiography,	acute,	no./n	(%)																		 72/137	(52.6)														 65/125	(52.0)													Angiography	during	ICU	stay,	no./n	(%)																		 10/137	(7.3)															 8/125	(6.4)															Angiography	after	ICU	stay,	no./n	(%)																		 4/137	(2.9)																 4/125	(3.2)															PCI	performed,	no./n	(%)																		 50/89	(56.2)															 41/80	(51.2)														CABG	performed,	no./n	(%)																		 5/88	(5.7)																	 1/81	(1.2)																IABP	performed,	no./n	(%)																																																		 5/130	(3.8)																 6/124	(4.8)															Abbreviations:	IQR=inter	quartile	range.	ROSC=return	of	spontaneous	circulation.	SpO2=peripheral	oxygen	saturation.	EtCO2=endtidal	carbon	dioxide.	LBBB=left	bundle	branch	block.	PCI=percutaneous	coronary	intervention.	CABG=coronary	artery	bypass	graft.		a	Only	in	patients	that	were	admitted	alive	at	hospital			
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Table	3.	Primary	and	Secondary	outcomes.					 																																																													 Intervention								 Control														 Difference	(95%	CI)	 Relative	Risk	(95%	CI)	 P	Value		 n=337	 n=334	 	 	 		 	 	 	 	 	
Primary	outcome																																													 	 	 	 	 	
Survival	with	CPC	1-2	at	90	days,	no./n	(%)																		 																				 																					 	 	 			All	patients																																															 56/337	(16.6)							 45/334	(13.5)								 3.1	(-2.3	to	8.5)	 1.23	(0.86	to	1.72)	 .25			Patients	with	shockable	rhythm																													 48/138	(34.8)							 35/135	(25.9)								 8.9	(-2.0	to	19.7)	 1.28	(0.90	to	1.72)	 .11			Patients	with	non-shockable	rhythm																									 8/198	(4.0)									 10/199	(5.0)									 -1.0	(-5.1	to	3.1)	 0.80	(0.32	to	1.97)	 .64																																																														 																				 																					 	 	 	
Secondary	outcomes																																											 																				 																					 	 	 	
Overall	survival	at	90	days,	no./n	(%)																							 																				 																					 	 	 			All	patients																																															 60/337	(17.8)							 52/334	(15.6)								 2.2	(-3.4	to	7.9)	 1.14	(0.81	to	1.57)	 .44			Patients	with	shockable	rhythm																													 51/138	(37.0)							 41/135	(30.4)								 6.6	(-4.6	to	17.8)	 1.18	(0.83	to	1.56)	 .25			Patients	with	non-shockable	rhythm																									 9/198	(4.5)									 11/199	(5.5)									 -1.0	(-5.3	to	3.3)	 0.82	(0.34	to	1.91)	 .65																																																														 																				 																					 	 	 	
Sustained	ROSC	and	admitted	to	hospital,	no./n	(%)											 																				 																					 	 	 			All	patients																																															 149/337	(44.2)						142/334	(42.5)							 1.7	(-5.8	to	9.2)	 1.04	(0.87	to	1.22)	 .66			Patients	with	shockable	rhythm																													 83/138	(60.1)							 78/135	(57.8)								 2.4	(-9.3	to	14.0)	 1.02	(0.82	to	1.21)	 .69			Patients	with	non-shockable	rhythm																									 65/198	(32.8)							 64/199	(32.2)								 0.7	(-8.5	to	9.9)	 1.03	(0.76	to	1.34)	 .89																																																														 																				 																					 	 	 	
Time	to	core	body	temp.	<34ºC,	minutes,	median	[IQR]	(n)		 																				 																					 	 	 			All	patients																																															 105	[80,	183]			 182	[132,	312]			 -70	(-100	to	-44)	 0.59	(0.49	to	0.71)	 <.001			Patients	with	shockable	rhythm																													 110	[80,	192]			 236	[158,	415]			 -102	(-169	to	-60)	 0.52	(0.39	to	0.65)	 <.001			Patients	with	non-shockable	rhythm																									 99	[82,	166]				 152	[125,	202]			 -50	(-86	to	-16)	 0.66	(0.50	to	0.87)	 .004																																																														 																				 																					 	 	 	
 
Abbreviations: Shockable rhythm = ventricular fibrillation or pulseless ventricular tachycardia. ROSC=return of spontaneous circulation. IQR=inter quartile range.  
